HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Bupivacaine Hydrochloride

HCID 64737
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
14252-80-3
Standard SMILES
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C.Cl
InChIKey
SIEYLFHKZGLBNX-UHFFFAOYSA-N
Molecular formula
C18H29ClN2O
Average molar mass
324.9 g/mol
Monoisotopic mass
324.1968412

Overview

Bupivacaine hydrochloride (anhydrous) is a racemate composed of equimolar amounts of dextrobupivacaine hydrochloride and levobupivacaine hydrochloride. The monohydrate form is commonly used as a local anaesthetic. It has a role as a local anaesthetic, an EC 3.1.1.8 (cholinesterase) inhibitor, an adrenergic antagonist, an amphiphile and an EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor. It contains a levobupivacaine hydrochloride (anhydrous), a dextrobupivacaine hydrochloride (anhydrous) and a bupivacaine(1+).

Names & identifiers

Preferred name
Bupivacaine Hydrochloride
IUPAC
1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide;hydrochloride
English name
Bupivacaine hydrochloride
Molecular formula
C18H28N2O.ClH
Molecular weight
324.89

Names & synonyms

Bupivacaine hydrochlorideBupivacaine HCL18010-40-7MarcaineCarbostesinMarcainMarcaine SpinalXaracollWin 11,318Bupivacaine hydrochloride anhydrousBupivacaine hydrochloride kitLAC-43
Show more names
SensorcaineBupivacaine HCIBupivocoine HClBupivacaine HCL APImarcainehydrochlorideBupivacaine HCL (USP)Bupivacaine Hydrochloride, USPBupivacaine hydrochloride,>98%
AH-2250Bupivacaini hydrochloridumNSC-758631AKA908P8J1bupivacaine hydrochloride (anhydrous)1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide monohydrochlorideDTXSID0030877CHEBI:31322

Database identifiers

CAS
14252-80-3、15233-43-9、18010-40-7
PubChem CID
64737
DTXSID
DTXSID0030877
ChEMBL
CHEMBL1200396

Properties

Computed structural properties

Topological polar surface area
32.3 Ų
Hydrogen bond donors
2
Hydrogen bond acceptors
2
Rotatable bonds
5
Heavy atoms
22
Formal charge
0
Complexity
321

Experimental & physicochemical properties

Human Drugs · 2 items

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Collision Cross Section171.6 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physicochemical properties

Melting point
249 · 249-2510C
storage temp.
Refrigerator
solubility
Soluble in water, freely soluble in alcohol.
form
Solid
color
White to Off-White
Stability
Hygroscopic
InChI
InChI=1S/C18H28N2O.ClH/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3;/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21);1H
InChIKey
SIEYLFHKZGLBNX-UHFFFAOYSA-N
SMILES
C1(CCCCN1CCCC)C(=O)NC1C(C)=CC=CC=1C.Cl
CAS DataBase Reference
14252 · 14252-80-3(CAS DataBase Reference)

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H300 (99.1%): Fatal if swallowed [Danger Acute toxicity, oral]

P264, P264+P265, P270, P273, P280, P301+P316, P305+P351+P338, P321, P330, P337+P317, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 116 reports by companies from 9 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory Information · 1 item

2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, monohydrochloride: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Hazard Classes and CategoriesAcute Tox. 2 (99.1%)

Toxicology

Treatment · 1 item

If the compound has been ingested, rapid gastric lavage should be performed using 5% sodium bicarbonate. For skin contact, the skin should be washed with soap and water. If the compound has entered the eyes, they should be washed with large quantities of isotonic saline or water. In serious cases, atropine and/or pralidoxime should be administered. Anti-cholinergic drugs work to counteract the effects of excess acetylcholine and reactivate AChE. Atropine can be used as an antidote in conjunction with pralidoxime or other pyridinium oximes (such as trimedoxime or obidoxime), though the use of '-oximes' has been found to be of no benefit, or possibly harmful, in at least two meta-analyses. Atropine is a muscarinic antagonist, and thus blocks the action of acetylcholine peripherally.

Chemistry & industry

Pharmacology

Metabolism/Metabolites · 1 item

Amide-type local anesthetics such as bupivacaine are metabolized primarily in the liver via conjugation with glucuronic acid. The major metabolite of bupivacaine is 2,6-pipecoloxylidine, which is mainly catalyzed via cytochrome P450 3A4. Route of Elimination: Only 6% of bupivacaine is excreted unchanged in the urine. Half Life: 2.7 hours in adults and 8.1 hours in neonates

FDA Pharmacological Classification · 6 items

0.25% BUPIVACAINE HCL

Amide Local Anesthetic [EPC]; Amides [CS]; Local Anesthesia [PE]

BUPIVACAINE HCI

Local Anesthesia [PE]; Amide Local Anesthetic [EPC]; Amides [CS]

BUPIVACAINE HCL

Local Anesthesia [PE]; Amides [CS]; Amide Local Anesthetic [EPC]

MeSH Pharmacological Classification · 1 item

Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate.

Uses & manufacturing

UsesFor the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures.

Applications

Usesantineoplastic

UsesBupivacaine Hydrochloride is the salt form of Bupivacaine (B689561); is a sodium channel blocker, local anesthetic.

Related reactions

6 records
New reaction record
HRID 41862 reaction equation
HRID 41862As reactant
HRID 1352188 reaction equation
HRID 1352188As reactant
HRID 1699646 reaction equation
HRID 1699646As reactant
HRID 1886742 reaction equation
HRID 1886742As reactant
HRID 2059964 reaction equation
HRID 2059964As reactant
HRID 2220784 reaction equation
HRID 2220784As reactant

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
ChEBI
CHEBI:31322
UNII
AKA908P8J1
EC Number
241-917-8
NCI Dictionary of Cancer Terms
bupivacaine hydrochloride; Sensorcaine
FDA UNII
7 TQO7W3VT8 · 7TQO7W3VT8
NCI Drug Dictionary
bupivacaine hydrochloride
Symbol(GHS)
6 · GHS06
Signal word
Danger
Hazard statements
330 · H330-H300-H310
Precautionary statements
264 · P264-P270-P301+P310-P321-P330-P405-P501-P260-P271-P284-P304+P340-P310-P320-P403+P233-P405-P501-P262-P264-P270-P280-P302+P350-P310-P322-P361-P363-P405-P501
Hazard Codes
T+
Risk Statements
26 · 26/27/28
Safety Statements
22 · 22-36/37/39-45
RIDADR
2811 · UN 2811 6.1/PG 2
WGK Germany
3 · 3
RTECS
6125000 · TK6125000
HazardClass
6.1 · 6.1(b)
PackingGroup
III
HS Code
2933399090 · 2933399090
Toxicity
50 in · LD50 in mice (mg/kg): 7.8 i.v., 82 s.c. (Henn, Brattsand)
Health Effects · 1 item

Acute exposure to cholinesterase inhibitors can cause a cholinergic crisis characterized by severe nausea/vomiting, salivation, sweating, bradycardia, hypotension, collapse, and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. Accumulation of ACh at motor nerves causes overstimulation of nicotinic expression at the neuromuscular junction. When this occurs symptoms such as muscle weakness, fatigue, muscle cramps, fasciculation, and paralysis can be seen. When there is an accumulation of ACh at autonomic ganglia this causes overstimulation of nicotinic expression in the sympathetic system. Symptoms associated with this are hypertension, and hypoglycemia. Overstimulation of nicotinic acetylcholine receptors in the central nervous system, due to accumulation of ACh, results in anxiety, headache, convulsions, ataxia, depression of respiration and circulation, tremor, general weakness, and potentially coma. When there is expression of muscarinic overstimulation due to excess acetylcholine at muscarinic acetylcholine receptors symptoms of visual disturbances, tightness in chest, wheezing due to bronchoconstriction, increased bronchial secretions, increased salivation, lacrimation, sweating, peristalsis, and urination can occur. Certain reproductive effects in fertility, growth, and development for males and females have been linked specifically to organophosphate pesticide exposure. Most of the research on reproductive effects has been conducted on farmers working with pesticides and insecticdes in rural areas. In females menstrual cycle disturbances, longer pregnancies, spontaneous abortions, stillbirths, and some developmental effects in offspring have been linked to organophosphate pesticide exposure. Prenatal exposure has been linked to impaired fetal growth and development. Neurotoxic effects have also been linked to poisoning with OP pesticides causing four neurotoxic effects in humans: cholinergic syndrome, intermediate syndrome, organophosphate-induced delayed polyneuropathy (OPIDP), and chronic organophosphate-induced neuropsychiatric disorder (COPIND). These syndromes result after acute and chronic exposure to OP pesticides.

Exposure Routes · 1 item

Epidural, Intraspinal, Infiltration. The rate of systemic absorption of local anesthetics is dependent upon the total dose and concentration of drug administered, the route of administration, the vascularity of the administration site, and the presence or absence of epinephrine in the anesthetic solution.

Toxicity Summary · 1 item

Bupivacaine is a cholinesterase or acetylcholinesterase (AChE) inhibitor. A cholinesterase inhibitor (or 'anticholinesterase') suppresses the action of acetylcholinesterase. Because of its essential function, chemicals that interfere with the action of acetylcholinesterase are potent neurotoxins, causing excessive salivation and eye-watering in low doses, followed by muscle spasms and ultimately death. Nerve gases and many substances used in insecticides have been shown to act by binding a serine in the active site of acetylcholine esterase, inhibiting the enzyme completely. Acetylcholine esterase breaks down the neurotransmitter acetylcholine, which is released at nerve and muscle junctions, in order to allow the muscle or organ to relax. The result of acetylcholine esterase inhibition is that acetylcholine builds up and continues to act so that any nerve impulses are continually transmitted and muscle contractions do not stop. Among the most common acetylcholinesterase inhibitors are phosphorus-based compounds, which are designed to bind to the active site of the enzyme. The structural requirements are a phosphorus atom bearing two lipophilic groups, a leaving group (such as a halide or thiocyanate), and a terminal oxygen.

Signs and Symptoms · 1 item

Recent clinical data from patients experiencing local anesthetic induced convulsions demonstrated rapid development of hypoxia, hypercarbia, and acidosis with bupivacaine within a minute of the onset of convulsions. These observations suggest that oxygen consumption and carbon dioxide production are greatly increased during local anesthetic convulsions and emphasize the importance of immediate and effective ventilation with oxygen which may avoid cardiac arrest.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Toxicity DataThe mean seizure dosage of bupivacaine in rhesus monkeys was found to be 4.4 mg/kg with mean arterial plasma concentration of 4.5 mcg/mL. LD50: 6 to 8 mg/kg (intravenous, mice) LD50: 38 to 54 mg/kg (subcutaneous, mice)

Safety data

wgk
3
rtecs
TK6125000
ridadr
UN 2811 6.1/PG 2
hs_code
2933399090
Toxicity
LD50 in mice (mg/kg): 7.8 i.v., 82 s.c. (Henn, Brattsand)
risk_code
26/27/28
Signal word
Danger
Symbol(GHS)
GHS06
hazard_code
T+
safety_code
22-36/37/39-45
hazard_class
6.1(b)
packing_group
III
Hazard statements
H330-H300-H310
Precautionary statements
P264-P270-P301+P310-P321-P330-P405-P501-P260-P271-P284-P304+P340-P310-P320-P403+P233-P405-P501-P262-P264-P270-P280-P302+P350-P310-P322-P361-P363-P405-P501
Additional notes · 1 item

DefinitionChEBI: Bupivacaine hydrochloride (anhydrous) is a racemate composed of equimolar amounts of dextrobupivacaine hydrochloride and levobupivacaine hydrochloride. The monohydrate form is commonly used as a local anaesthetic. It has a role as an adrenergic antagonist, an amphiphile, an EC 3.1.1.8 (cholinesterase) inhibitor, an EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor and a local anaesthetic. It contains a levobupivacaine hydrochloride (anhydrous), a dextrobupivacaine hydrochloride (anhydrous) and a bupivacaine(1+).